Home / Business and Economy / Abbott Labs Partners for Alzheimer's Testing
Abbott Labs Partners for Alzheimer's Testing
25 Jun
Summary
- ALZpath and Abbott Laboratories formed a global licensing agreement.
- The partnership aims to advance blood-based Alzheimer's disease testing.
- This collaboration seeks to provide easier diagnostic options for Alzheimer's.
ALZpath and Abbott Laboratories have established a global licensing agreement, announced on Wednesday, June 24, 2026. This significant collaboration aims to propel the advancement of blood-based testing for Alzheimer's disease.
The partnership between the two entities is focused on developing and offering more user-friendly diagnostic options for Alzheimer's. This effort is part of a broader industry race to create accessible tools for identifying the brain-wasting disease.
This agreement signifies a crucial step towards improving the diagnostic landscape for Alzheimer's. The goal is to make testing simpler and more widely available to patients.
As of June 25, 2026, the situation indicates an ongoing commitment to innovation in Alzheimer's diagnostics.
